Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Chief Science & Tech. Officer | August 12, 2020 | August 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date August 12, 2020 · Filed August 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.55 · Expires 2030-08-12 | Direct | 50,000 |
Reported balance
After 2020-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-12 · Grant · Acquired 50,000 · Balance 50,000 F1: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.
F2: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2020 Filed Aug 14, 2020 21:03 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-20-022314 · ownership.xml · derivative · entry 1 Ludwig Dale L. · CIK 0001727406 · Chief Science & Tech. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-08-12 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 21:13 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 400,000 | $0.23 Strike: $0.23 | $92,800.00 |
DisclosureSEC source: 0001213900-19-012884 · ownership.xml · derivative · entry 1 Ludwig Dale L. · CIK 0001727406 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 22:08 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 10,000 | $0.45 | $4,499.00 |
DisclosureSEC source: 0001213900-18-016321 · ownership.xml · nonDerivative · entry 1 Ludwig Dale L. · CIK 0001727406 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.